Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Afamelanotide for erythropoietic protoporphyria
J. G. Langendonk
,
M. Balwani
, K. E. Anderson
, H. L. Bonkovsky
, A. V. Anstey
, D. M. Bissell
, J. Bloomer
, C. Edwards
, N. J. Neumann
, C. Parker
, J. D. Phillips
, H. W. Lim
, I. Hamzavi
, J. C. Deybach
, R. Kauppinen
, L. E. Rhodes
, J. Frank
, G. M. Murphy
, F. P.J. Karstens
, E. J.G. Sijbrands
F. W.M. De Rooij,
M. Lebwohl
, H. Naik, C. R. Goding, J. H.P. Wilson,
R. J. Desnick
Show 6 others
Show less
Friedman Brain Institute
Genetics and Genomic Sciences
Icahn Genomics Institute
Icahn School of Medicine at Mount Sinai
Waldman Department of Dermatology
Graduate School of Biomedical Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
241
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Afamelanotide for erythropoietic protoporphyria'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Afamelanotide
100%
Erythropoietic Protoporphyria
100%
Quality of Life
44%
Sun Exposure
33%
Adverse Events
22%
Placebo Groups
22%
Pain Duration
22%
Free Time
22%
Subcutaneous Implantation
22%
European Union Studies
22%
Phototoxic Reaction
22%
United States
11%
Placebo
11%
Serious Adverse Events
11%
Randomized Placebo-controlled Trial
11%
Trial Quality
11%
European Union
11%
Quality of Life Improvement
11%
Adverse Events Profile
11%
Validated Questionnaire
11%
Hormone Analogs
11%
α-Melanocyte-stimulating Hormone (α-MSH)
11%
Direct Exposure
11%
Photodermatoses
11%
Phototoxicity
11%
Photoprovocation
11%
Pharmacology, Toxicology and Pharmaceutical Science
Afamelanotide
100%
Erythropoietic Protoporphyria
100%
Adverse Event
44%
Placebo
44%
Implant
33%
Sun Exposure
22%
Hormone Analog
11%
Photodermatosis
11%
Intermedin
11%
Phototoxicity
11%
Side Effect
11%